Table 4.

Methylation levels in Selected Genes and RCC recurrence Risk

	Discovery Set				Validation Set
	RCC patients (n=63)				RCC patients (n=177)
Marker	Recurrence n(%)	No Recurrence n(%)	HR*(95%CI)	p value	Recurrence n(%)	No Recurrence n(%)	HR*(95%CI)	p value
NPY
Low	7(22.58)	24(77.42)	1(ref)		17(19.32)	71(80.68)	1(ref)
High	8(25.00)	24(75.00)	0.94(0.31–2.80)	0.91	14(15.73)	75(84.27)	1.16(0.53–2.54)	0.71
LEP
Low	2(6.25)	30(93.75)	1(ref)		11(12.36)	78(87.64)	1(ref)
High	13(41.94)	18(58.06)	5.14(1.07–24.66)	0.04	20(22.73)	68(77.27)	1.48(0.66–3.32)	0.34
LEPR
Low	3(9.38)	29(90.63)	1(ref)		8(9.09)	80(90.91)	1(ref)
High	12(38.71)	19(61.29)	1.02(0.14–7.71)	0.98	23(25.84)	66(74.16)	3.15(1.23–8.07)	0.02
	ccRCC patients (n=48)				ccRCC patients (n=143)
NPY
Low	7(29.17)	17(70.83)	1(ref)		14(19.72)	57(80.28)	1(ref)
High	6(25.00)	18(75.00)	1.70(0.39–7.40)	0.48	10(13.89)	62(86.11)	1.05(0.42–2.62)	0.91
LEP
Low	2(8.33)	22(91.67)	1(ref)		9(12.50)	63(87.50)	1(ref)
High	11(45.83)	13(54.17)	5.96(1.02–34.76)	0.05	15(21.13)	56(78.87)	1.41(0.58–3.42)	0.44
LEPR
Low	2(8.33)	22(91.67)	1(ref)		6(8.33)	66(91.67)	1(ref)
High	11(45.83)	13(54.17)	1.59(0.22–11.59)	0.65	18(25.35)	53(74.65)	6.00(1.92–18.82)	2.00E-03

HR* Multivariate regression model adjusted by age, gender, stage, grade, smoking status, BMI, hypertension and histology